Aptose Reports Results for the Third Quarter 2023
Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance Mechanisms TUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated a...